161 related articles for article (PubMed ID: 38423050)
1. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis.
Gharzai LA; Morris E; Suresh K; Nguyen-Tân PF; Rosenthal DI; Gillison ML; Harari PM; Garden AS; Koyfman S; Caudell JJ; Jones CU; Mitchell DL; Krempl G; Ridge JA; Gensheimer MF; Bonner JA; Filion E; Dunlap NE; Stokes WA; Le QT; Torres-Saavedra P; Mierzwa M; Schipper MJ
Lancet Oncol; 2024 Mar; 25(3):366-375. PubMed ID: 38423050
[TBL] [Abstract][Full Text] [Related]
2. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
Gharzai LA; Jiang R; Wallington D; Jones G; Birer S; Jairath N; Jaworski EM; McFarlane MR; Mahal BA; Nguyen PL; Sandler H; Morgan TM; Reichert ZR; Alumkal JJ; Mehra R; Kishan AU; Fizazi K; Halabi S; Schaeffer EM; Feng FY; Elliott D; Dess RT; Jackson WC; Schipper MJ; Spratt DE
Lancet Oncol; 2021 Mar; 22(3):402-410. PubMed ID: 33662287
[TBL] [Abstract][Full Text] [Related]
3. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.
Mauguen A; Pignon JP; Burdett S; Domerg C; Fisher D; Paulus R; Mandrekar SJ; Belani CP; Shepherd FA; Eisen T; Pang H; Collette L; Sause WT; Dahlberg SE; Crawford J; O'Brien M; Schild SE; Parmar M; Tierney JF; Le Pechoux C; Michiels S;
Lancet Oncol; 2013 Jun; 14(7):619-26. PubMed ID: 23680111
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
5. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
Michiels S; Le Maître A; Buyse M; Burzykowski T; Maillard E; Bogaerts J; Vermorken JB; Budach W; Pajak TF; Ang KK; Bourhis J; Pignon JP;
Lancet Oncol; 2009 Apr; 10(4):341-50. PubMed ID: 19246242
[TBL] [Abstract][Full Text] [Related]
6. Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
Jackson WC; Tang M; Schipper MJ; Sandler HM; Zumsteg ZS; Efstathiou JA; Shipley WU; Seiferheld W; Lukka HR; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Hall WA; Dess RT; Lovett RD; Balogh AG; Feng FY; Spratt DE
J Clin Oncol; 2022 Sep; 40(27):3172-3179. PubMed ID: 35737923
[TBL] [Abstract][Full Text] [Related]
7. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
[TBL] [Abstract][Full Text] [Related]
8. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis.
Mehanna H; Taberna M; von Buchwald C; Tous S; Brooks J; Mena M; Morey F; Grønhøj C; Rasmussen JH; Garset-Zamani M; Bruni L; Batis N; Brakenhoff RH; Leemans CR; Baatenburg de Jong RJ; Klussmann JP; Wuerdemann N; Wagner S; Dalianis T; Marklund L; Mirghani H; Schache A; James JA; Huang SH; O'Sullivan B; Nankivell P; Broglie MA; Hoffmann M; Quabius ES; Alemany L;
Lancet Oncol; 2023 Mar; 24(3):239-251. PubMed ID: 36796393
[TBL] [Abstract][Full Text] [Related]
11. Conditional copula models for correlated survival endpoints: Individual patient data meta-analysis of randomized controlled trials.
Emura T; Sofeu CL; Rondeau V
Stat Methods Med Res; 2021 Dec; 30(12):2634-2650. PubMed ID: 34632882
[TBL] [Abstract][Full Text] [Related]
12. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials.
Fakhry C; Zhang Q; Gillison ML; Nguyen-Tân PF; Rosenthal DI; Weber RS; Lambert L; Trotti AM; Barrett WL; Thorstad WL; Yom SS; Wong SJ; Ridge JA; Rao SSD; Spencer S; Fortin A; Raben D; Harris J; Le QT
Cancer; 2019 Jun; 125(12):2027-2038. PubMed ID: 30913305
[TBL] [Abstract][Full Text] [Related]
13. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma.
Howard J; Masterson L; Dwivedi RC; Riffat F; Benson R; Jefferies S; Jani P; Tysome JR; Nutting C
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD010963. PubMed ID: 27943254
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
15. Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer.
Xie W; Ravi P; Buyse M; Halabi S; Kantoff P; Sartor O; Soule H; Clarke N; Dignam J; James N; Fizazi K; Gillessen S; Mottet N; Murphy L; Parulekar W; Sandler H; Tombal B; Williams S; Sweeney CJ
Ann Oncol; 2024 Mar; 35(3):285-292. PubMed ID: 38061427
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
17. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.
Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2017 Mar; 143(3):253-259. PubMed ID: 27918781
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
[TBL] [Abstract][Full Text] [Related]
20. Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.
Zhang Z; Pan Q; Lu M; Zhao B
EClinicalMedicine; 2023 Sep; 63():102156. PubMed ID: 37600482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
